FindTrial
Sign In

BREEZE

A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase 2b Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221030
Enrollment
Unknown
Registered
2010-03-01
Start date
2010-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

investigational material(s) Generic name etc : AZD9668 INN of investigational material : Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Administration for Invest

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Diagnosis of COPD with symptoms over 1 year - Smokers or ex-smokers - Males or post-menopausal females between 40 and 80 years old - Able to use electronic device

Exclusion criteria

Exclusion criteria: - Past history or current evidence of clinically significant heart disease - Current diagnosis of asthma - Patients who require long term oxygen therapy - Treatment with antibiotics within 4 weeks of study visit 1b

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026